𝐋𝐞𝐧𝐳 𝐓𝐡𝐞𝐫𝐚𝐩𝐞𝐮𝐭𝐢𝐜𝐬 𝐌𝐞𝐫𝐠𝐞𝐬 𝐖𝐢𝐭𝐡 𝐆𝐫𝐚𝐩𝐡𝐢𝐭𝐞 𝐁𝐢𝐨
💉 🤝 Four months following the initiation of a definitive merger agreement, LENZ Therapeutics and Graphite Bio have seamlessly amalgamated under a singular identity. With a primary focus on addressing presbyopia, Lenz Therapeutics aims to propel its ground breaking preservative-free, single-use, once-daily eye drops forward. These therapeutics candidates, LNZ199 (1.75% aceclidine) and LNZ101 (1.75% aceclidine and brimonidine), represent significant strides in presbyopia management. The merger signifies a concerted effort to advance research and development in the realm of presbyopia treatment, promising innovative solutions to enhance vision and quality of life for affected individuals.